Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Aug 16,2021
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Recently, Loxo Oncology, a research and development group of Eli Lilly, and Kumquat Biosciences (Kumquat) announced that the two parties have reached an exclusive collaboration
More
Kumquat Biosciences and Eli Lilly have reached a partnership to jointly develop tumor immune small molecule drugs
Aug 16,2021
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
On August 4, 2021, Mr. Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team visited Shanghai Medicilon Inc. (Medicilon) at
More
Qing Ruan, Deputy Director of Shanghai Municipal Development and Reform Commission, and his team examined Medicilon
Aug 13,2021
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Recently, Shanghai Ringene Biopharma (Ringene) announced that the company's self-developed anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical
More
Medicilon assists Ringene Biopharma 's SHP2 allosteric inhibitor RG001 tablet to be approved for clinical use
Aug 06,2021
Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels
On July 28, 2021, the Class 1 innovative drug LDS tablets developed by Shanghai Leado Pharma Technology Co., Ltd. (Leado Pharma) received the National Medical
More
Medicilon assists Leado Pharma to obtain clinical approval for small molecule inhibitor LDS tablets targeting transient receptor potential channels
Jul 16,2021
[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials
Recently, Changzhou Qianhong Bio-Pharma targeted anti-cancer Class 1 new drug QHRD110 capsules was approved for clinical trials.
More
[Medicilon Assist] QHRD110 Capsules, a Class 1 Anti-cancer Drug Targeted by Qianhong, was Approved for Clinical Trials
Jul 06,2021
Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval
Recently, a recombinant humanized anti-MUC1 monoclonal antibody-Tub201 coupling agent (hereinafter referred to as "Muc1") for the treatment of advanced solid tumor class 1 ADC drug injection from Dac Biotechnology was approved for clinical use. This is the first clinically approved Muc1-ADC drug in China.
More
Medicilon Helps Hangzhou Dac Biotechnology Muc1-ADC Get Clinical Approval
Jun 30,2021
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Recently, the orphan drug KBMAB-16 (intravenous injection of tumor necrosis factor-α inhibitor), a major project of a well-known Chinese pharmaceutical company located in Chengdu, was successfully approved for clinical trial application (IND) by the US Food and Drug Administration (US FDA).
More
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Jun 25,2021
Medicilon's "New Drugs + AI Innov Forum" was successful held
When AI accurately predicts the "difficult” protein 3D structure; When AI completes the new drug design within 21 days; When AI discovers a new mechanism
More
Medicilon's "New Drugs + AI Innov Forum" was successful held
Jun 08,2021
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use.
More
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
May 14,2021
Safety assessment lab of process chemistry
Safety assessment lab of process chemistry In the research and development process of innovative drugs, the chemical process research of drugs plays a pivotal role. 
More
Safety assessment lab of process chemistry
May 01,2021
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
On July 15, 2021, Vastpro and Medicilon signed a strategic cooperation agreement in the Medicilon Chuansha Park to reach a long-term strategic cooperation relationship.Vastpro president
More
Vastpro and Medicilon signed a strategic cooperation agreement for pre-clinical IND application services
Apr 25,2021
Medicilon Appoints Two Vice Presidents
Shanghai Medicilon Inc. recently assigned Dr. Haifeng Yin as the vice president of process chemistry and formulation study, Dr. Baohong Cao as the vice president
More
Medicilon Appoints Two Vice Presidents